Sedative-Hypnotic Toxicity

Sedative-hypnotic toxicity encompasses poisoning from benzodiazepines, barbiturates, non-benzodiazepine "Z-drugs" (zolpidem, zaleplon, zopiclone), GHB, chloral hydrate, and older agents (glutethimide, ethchlorvynol, meprobamate). The hallmark is CNS depression ranging from drowsiness to coma, with respiratory compromise as the primary mechanism of death.[1-3] Isolated benzodiazepine overdose rarely causes life-threatening hemodynamic instability; most fatalities involve co-ingestion with opioids, alcohol, or other CNS depressants.[1-2] Barbiturates carry a significantly narrower therapeutic index and higher lethality than benzodiazepines.[4-5]

1. History

• Substance identification: Which agent(s), dose, formulation (immediate vs. extended release), route (oral, IV, rectal)
• Timing: Time of ingestion relative to presentation; single acute vs. staggered ingestion
• Intent: Accidental, recreational, or intentional (suicidal) — critical for disposition[6]
• Co-ingestants: Opioids, alcohol, TCAs, acetaminophen, other OTC medications — polysubstance ingestion is the rule, not the exception[2]
• Symptom progression: Drowsiness → confusion → slurred speech → ataxia → stupor → coma[3][5]
• Associated symptoms: Nausea/vomiting, anterograde amnesia, paradoxical agitation (rare)[3][5]
• Important negatives: Chest pain, seizure activity, trauma/falls during intoxication

2. Alarm Features

• Respiratory depression or apnea — the primary killer[1-2]
• Loss of protective airway reflexes (absent gag, pooling secretions)
• Hemodynamic instability (hypotension, bradycardia) — suggests barbiturate overdose, massive ingestion, or co-ingestant[5][7]
• Hypothermia[3][8]
• Markedly abnormal vital signs (lowered or elevated BP, HR, or RR) raise concern for additional drugs or alcohol[3]
• Fluctuating level of consciousness — classic for highly lipophilic older agents (glutethimide, ethchlorvynol) due to enterohepatic recirculation[4]
• Pulmonary edema or circulatory collapse — seen with massive barbiturate exposure[9-10]

3. Medications

Causative agents (by class)

• Benzodiazepines: alprazolam, diazepam, lorazepam, midazolam, clonazepam, etc.
• Barbiturates: phenobarbital, pentobarbital, secobarbital, butalbital
• Z-drugs: zolpidem, zaleplon, zopiclone/eszopiclone
• Others: GHB/GBL, chloral hydrate, meprobamate, glutethimide, ethchlorvynol
• Novel benzodiazepines: clonazolam, flualprazolam, etizolam (increasingly found in counterfeit pills)[11]

Antidote — Flumazenil (benzodiazepine-specific)

• Dose: 0.2 mg IV over 30 seconds, may repeat 0.3 mg then 0.5 mg increments q1 min, max 3 mg in overdose[12]
• Contraindications: chronic benzodiazepine dependence, co-ingestion of seizure-provoking drugs (TCAs), epilepsy on benzodiazepines, undifferentiated coma[1-2][12]
• Safe in low-risk settings: iatrogenic procedural sedation reversal, pediatric exploratory ingestions[1-2]
• Does not reverse barbiturate, GHB, or other non-benzodiazepine sedative toxicity

Medications to avoid

• Flumazenil in undifferentiated coma or suspected TCA co-ingestion (risk of refractory seizures and dysrhythmias)[1][12]
• Long-acting paralytics for RSI (may mask seizures) — prefer succinylcholine or rocuronium[6]

4. Diet

• NPO in obtunded patients due to aspiration risk
• Hydration: IV crystalloid for volume support; avoid oral intake until airway protective reflexes return
• No specific dietary triggers; however, alcohol co-ingestion synergistically potentiates CNS depression[1-2]
• Long-term: counsel on avoidance of alcohol with prescribed sedative-hypnotics

5. Review of Systems

• Neurologic: Level of consciousness, confusion, amnesia, ataxia, slurred speech, seizures
• Respiratory: Dyspnea, apnea, snoring/stridor (airway obstruction)
• Cardiovascular: Palpitations, syncope, chest pain
• GI: Nausea, vomiting (aspiration risk)
• Psychiatric: Suicidal ideation, depression, substance use history
• Musculoskeletal: Prolonged immobilization → rhabdomyolysis, compartment syndrome
• Skin: Pressure blisters ("barb burns") from prolonged immobility — classically associated with barbiturate coma

6. Collateral History and Family History

• Collateral is critical when the patient cannot provide history: EMS, family, friends, pill bottles, medication lists, pharmacy records[6]
• Photographs of medications at the scene are invaluable
• Psychiatric history: Prior suicide attempts, depression, access to medications
• Substance use history: Chronic benzodiazepine or opioid use (determines flumazenil safety and withdrawal risk)[1][13]
• Family history: Substance use disorders, psychiatric illness, seizure disorders

7. Risk Factors

• Polysubstance use — the single greatest risk factor for mortality[1-2]
• Chronic benzodiazepine or opioid prescriptions
• Psychiatric comorbidities (depression, anxiety, personality disorders)[13]
• Elderly patients — increased sensitivity, fall risk, prolonged sedation[5]
• Hepatic or renal impairment — impaired drug metabolism/excretion
• History of prior overdose or suicide attempt
• Access to large quantities of sedative-hypnotics
• Use of illicit benzodiazepines (counterfeit pills containing novel benzodiazepines or fentanyl)[2][11]

8. Differential Diagnosis

• Opioid overdose — miosis, more profound respiratory depression; responds to naloxone[2]
• Alcohol intoxication — similar presentation; check ethanol level
• Hypoglycemia — check point-of-care glucose immediately[6]
• Carbon monoxide poisoning — altered mental status, headache; check carboxyhemoglobin[8]
• Anticholinergic toxidrome — dry, flushed, mydriasis, tachycardia (opposite of sedative-hypnotic)
• Hepatic encephalopathy — asterixis, elevated ammonia
• Postictal state — history of seizure disorder
• Structural CNS pathology — stroke, subdural hematoma (especially after fall while intoxicated)[5]
• Hypothyroidism/myxedema coma — hypothermia, bradycardia
• Sepsis/meningitis — fever, altered mental status
• Key distinguishing features: The sedative-hypnotic toxidrome classically presents with normal or small pupils (unlike opioid miosis), hypothermia, hypotension, respiratory depression, and hyporeflexia without the anticholinergic signs (dry skin, mydriasis, tachycardia).[5]

9. Past Medical History

• Chronic benzodiazepine or sedative use — determines tolerance, withdrawal risk, and flumazenil safety[1][12]
• Seizure disorder — flumazenil contraindicated if benzodiazepines are used for seizure control[12]
• Psychiatric history — depression, prior suicide attempts, personality disorders
• Substance use disorders — alcohol, opioids, polysubstance
• Hepatic disease — impaired metabolism of most sedative-hypnotics
• Chronic pain on opioids — high risk for synergistic respiratory depression
• Prior overdose history

10. Physical Exam

Vital signs

• Bradypnea/apnea — most critical finding
• Hypotension (especially barbiturates)
• Bradycardia (mild)
• Hypothermia[3][5]

Neurologic

• Decreased level of consciousness (GCS documentation essential)[6]
• Slurred speech, ataxia, nystagmus[5]
• Hyporeflexia, hypotonia
• Normal or small pupils (not pinpoint like opioids)
• Absent gag reflex in severe cases

Skin

• Pressure blisters ("barb burns") — bullous lesions over pressure points from prolonged immobility (classically barbiturates but not pathognomonic)
• Check for transdermal patches (fentanyl), track marks[6]

Focused maneuvers

• Assess airway patency and protective reflexes
• Check for signs of trauma (subdural hematoma from fall)
• Compartment checks if prolonged immobilization suspected

11. Lab Studies

• Point-of-care glucose — immediate, to rule out hypoglycemia[6]
• Serum acetaminophen and salicylate levels — mandatory in all intentional overdoses and undifferentiated altered mental status[6]
• BMP (electrolytes, creatinine, bicarbonate, anion gap)[6]
• ABG/VBG — assess for hypercapnia and respiratory acidosis; characterize acid-base status[6][14]
• Hepatic function panel — baseline and to evaluate for co-ingestant hepatotoxicity
• Serum ethanol level
• CK — if prolonged immobilization suspected (rhabdomyolysis)
• Pregnancy test — women of childbearing age[6]
• Barbiturate level — quantitative phenobarbital level useful for guiding enhanced elimination[7][15]
• Urine drug screen — limited acute utility; high false-positive/negative rates; does not detect novel benzodiazepines. Useful for confirming exposure but should not guide acute management.[6][11]
• Lactate — if hemodynamic instability

12. Imaging

• Chest X-ray: Indicated if hypoxic, tachypneic, or obtunded — evaluate for aspiration pneumonitis, ARDS, or pulmonary edema[6]
• CT head without contrast: If altered mental status is disproportionate to expected toxicity, concern for trauma/fall, or focal neurologic findings[5]
• Abdominal imaging: Generally not indicated; plain films have low sensitivity for most sedative-hypnotics. Consider CT abdomen if body packing suspected[6]
• Imaging is unnecessary in straightforward, witnessed benzodiazepine ingestions with expected clinical course

13. Special Tests

• Glasgow Coma Scale — serial assessments to track clinical trajectory[6]
• Poison Control consultation (800-222-1222) — recommended for all significant ingestions[6]
• Quantitative drug levels: Phenobarbital level is clinically useful (correlates with severity and guides enhanced elimination). Benzodiazepine levels are generally not clinically useful.[7][15]
• Bedside ultrasound: Assess cardiac function and IVC if hemodynamically unstable
• End-tidal CO₂ monitoring: Useful for detecting hypoventilation, especially during observation

14. ECG

• Obtain ECG in all significant sedative-hypnotic overdoses, especially with unknown co-ingestants[6]
• Isolated benzodiazepine/barbiturate overdose: Typically shows sinus bradycardia or normal sinus rhythm; no characteristic morphologic changes

Critical role is to rule out co-ingestants

• Prolonged QRS → sodium channel blocker (TCA) co-ingestion[6][16]
• Prolonged QTc → multiple psychotropic co-ingestants; QTc >500 ms is highest risk for adverse cardiovascular events[17-18]
• AV block → beta-blocker or calcium channel blocker co-ingestion
• Continuous cardiac monitoring recommended until the patient is free of drug influence[17]
• A QTc >500 ms on admission ECG in drug overdose carries an OR of 11.2 for adverse cardiovascular events[18]

15. Assessment

Severity stratification

• Mild: Drowsiness, slurred speech, ataxia — maintains airway and protective reflexes
• Moderate: Stupor, significant hypotension, diminished reflexes — requires close monitoring
• Severe: Coma, respiratory depression/apnea, hemodynamic collapse — requires airway intervention and ICU care

Key clinical pearls

• Isolated benzodiazepine overdose is rarely fatal in adults; always suspect co-ingestants when life-threatening features are present[1-2]
• Barbiturate overdose has a much narrower therapeutic index and higher mortality[4-5][7]
• Older lipophilic agents (glutethimide, ethchlorvynol) cause fluctuating consciousness due to enterohepatic recirculation — observe for several days[4]
• Long-acting benzodiazepines (diazepam, chlordiazepoxide) may cause intoxication lasting several days due to active metabolites[4]
• Novel/designer benzodiazepines (clonazolam) may cause prolonged sedation (up to 30 hours) and are not detected on standard immunoassay screens[11]

Complications

• Aspiration pneumonitis/pneumonia
• Rhabdomyolysis and compartment syndrome from prolonged immobilization
• Pressure injuries/blisters
• Hypothermia
• Anoxic brain injury (from prolonged hypoxia)

16. Treatment Plan

Initial stabilization (ABCs)

• Airway: Head-tilt/chin-lift, nasopharyngeal airway; intubate if unable to protect airway[1][6]
• Breathing: Bag-mask ventilation → endotracheal intubation if needed; supplemental O₂
• Circulation: IV access, crystalloid bolus for hypotension; vasopressors if refractory

Decontamination

• Activated charcoal (1 g/kg, max 50 g): Consider if within 1 hour of ingestion and airway is intact/protected[4][6]
• Multiple-dose activated charcoal (MDAC): Indicated for phenobarbital poisoning (reduces half-life from ~80 to ~40 hours)[6][15]

Antidote

• Flumazenil — reserved for low-risk, known benzodiazepine-only ingestions (e.g., iatrogenic procedural sedation, pediatric exploratory ingestion)[1-2][12]
• Dose: 0.2 mg IV over 30 sec → 0.3 mg → 0.5 mg increments q1 min, max 3 mg[12]
• Do not use in undifferentiated coma, chronic benzodiazepine users, suspected TCA co-ingestion, or seizure disorder patients on benzodiazepines[1][12]
• No antidote exists for barbiturates, GHB, or other non-benzodiazepine sedative-hypnotics

Enhanced elimination (barbiturates)

• Urinary alkalinization with IV sodium bicarbonate (target urine pH ~7.5) — enhances excretion of phenobarbital[4][15]
• Hemodialysis/CRRT: Consider for life-threatening barbiturate toxicity with refractory hypotension[14-15]

Supportive care

• Continuous pulse oximetry, capnography, cardiac monitoring
• Rewarming for hypothermia
• DVT prophylaxis if prolonged immobilization
• Frequent repositioning to prevent pressure injuries and rhabdomyolysis
• Psychiatric evaluation once medically cleared (if intentional ingestion)

17. Disposition

Admission criteria (ICU)

• Intubation or need for mechanical ventilation
• Hemodynamic instability requiring vasopressors
• Severe barbiturate poisoning requiring enhanced elimination
• GCS ≤8 or declining mental status
• Significant co-ingestants requiring monitoring (e.g., acetaminophen, TCAs)

Observation

• Moderate sedation with stable vitals — observe until clinically improving and able to protect airway
• Minimum 4–6 hours observation for short-acting agents; longer for long-acting benzodiazepines or barbiturates[4]
• Older lipophilic agents (glutethimide, ethchlorvynol) require several days of observation due to fluctuating levels[4]

Discharge criteria

• Alert, ambulatory, tolerating PO, stable vitals for appropriate observation period
• No respiratory depression
• Psychiatric clearance if intentional ingestion
• Safe disposition plan (not returning to environment with access to lethal means)

Specialist consultation triggers

• Toxicology/Poison Control: All significant ingestions[6]
• Psychiatry: All intentional overdoses
• Nephrology: If hemodialysis considered for barbiturate poisoning[14-15]

18. Follow Up / Return Precautions

Follow-up timing

• PCP or psychiatry follow-up within 48–72 hours for intentional ingestions
• Substance use disorder referral if applicable
• Medication reconciliation — reassess need for sedative-hypnotic prescriptions
• Return precautions — instruct patient/family to return immediately for:
• Recurrent drowsiness or difficulty arousing (especially with long-acting agents or if flumazenil was used, as re-sedation can occur)[12]
• Difficulty breathing or noisy breathing
• Confusion, agitation, or seizures (may indicate withdrawal in chronic users)[5][19]
• Fever, cough, or chest pain (aspiration pneumonitis)
• Dark urine or muscle pain (rhabdomyolysis)

Patient counseling

• Avoid alcohol and other CNS depressants
• Secure medications to prevent accidental pediatric ingestion
• Lethal means counseling and safe storage/disposal of unused medications
• Expected recovery: mild cases resolve within hours; long-acting agents may cause residual sedation for days[4]
• Relevant images 2 items
• Clinical Findings in Opioid Analgesic Intoxication.
• NEJM July 11, 2012
• (a) Minimally widened QRS complex in the setting of a cardiotoxic ingestion with sodium channel blocking ability. (b) Tricyclic antidepressant overdose with characteristic changes on ECG, including sinus tachycardia, deep S wave in lead I, R wave in lead aVr, and widened QRS complex. (c) Ventricular tachycardia related to sodium channel blockade.
• Electrocardiagram in Emergency and Acute Care December 31, 2022

References

1. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.

2. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.

3. FDA Drug Label. — Updated date: 2025-04-29. Food and Drug Administration.

4. Role of the Primary Care Physician in Problems of Substance Abuse. — Weaver MF, Jarvis MA, Schnoll SH. Archives of Internal Medicine. 1999.

5. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.

6. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.

7. FDA Drug Label. — Updated date: 2017-06-30. Food and Drug Administration.

8. Toxin-Induced Coma and Central Nervous System Depression. — Krause M, Hocker S. Neurologic Clinics. 2020.

9. FDA Drug Label. — Updated date: 2026-05-05. Food and Drug Administration.

10. FDA Drug Label. — Updated date: 2026-01-28. Food and Drug Administration.

11. Non-Fatal Intoxications Involving the Novel Benzodiazepine Clonazolam: Case Series From the Emerging Drugs Network of Australia - Victoria Project. — Syrjanen R, Greene SL, Castle JW, et al. Clinical Toxicology. 2023.

12. FDA Drug Label. — Updated date: 2020-01-03. Food and Drug Administration.

13. The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations when Benzodiazepine Risks Outweigh Benefits. — Emily Brunner, Chwen-Yuen A. Chen, Tracy Klein, et al American College of Medical Toxicology (2024). 2024.

14. Poisoning by Abnormally High Blood Phenobarbital Concentration Treated With Extracorporeal Therapy. — Kohara S, Kamijo Y, Seki S, Hasegawa E. The American Journal of Emergency Medicine. 2023.

15. Enhanced Elimination in Acute Barbiturate Poisoning - A Systematic Review. — Roberts DM, Buckley NA. Clinical Toxicology. 2011.

16. Electrocardiographic Abnormalities Associated With Poisoning. — Delk C, Holstege CP, Brady WJ. The American Journal of Emergency Medicine. 2007.

17. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.

18. Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose. — Manini AF, Nair AP, Vedanthan R, Vlahov D, Hoffman RS. Journal of the American Heart Association. 2017.

19. Guidelines for Managing Substance Withdrawal in Jails. — Jeffrey Alvarez MD CCHP, Andrew F. Angelino MD, Oscar Aviles CPM CJM CCE CCHP, et al American Society of Addiction Medicine (2023). 2023.